Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|BTX-A51||BTXA51||CDK7 Inhibitor 13 CDK9 Inhibitor 16||BTX-A51 is a small molecule inhibitor of CSNK1A1, CDK7, and CDK9, which may lead to Tp53 stabilization and apoptotic induction, inhibition of colony formation, and antitumor activity (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT04243785||Phase I||BTX-A51||A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome||Recruiting|